Harrow Inc., a Nashville-based pharmaceutical company specializing in ophthalmic medications, filed a current report with the Securities and Exchange Commission on November 16, 2026. The filing included a corporate presentation detailing the company’s strategic objectives and operational progress.
The company’s strategic focus is centered on three core ophthalmic products, supported by an expanding commercial platform. Harrow Inc. has outlined a pipeline of new product launches scheduled through 2030. The presentation identified specific growth opportunities within the dry eye, retinal, and surgical markets.
Regarding operational performance, the report noted recent revenue growth and improvements in operating leverage. Management indicated that sales teams have been expanded while maintaining costs that do not rise proportionally to the increase in personnel. Furthermore, the company addressed forthcoming regulatory submissions and anticipated product approvals.
As of the market close on November 16, 2026, Harrow Inc. was trading on the Nasdaq at a price of 29.52 USD. The company maintains a market capitalization of 1,090,000,000 USD. Over the past 52 weeks, the stock has reached a high of 54.85 USD and a low of 25.76 USD. The company’s price-to-earnings ratio is reported at -38.22.




